We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.23B
AUM Growth
+$1.54B
Cap. Flow
+$1.36B
Cap. Flow %
42.13%
Top 10 Hldgs %
68.77%
Holding
142
New
24
Increased
22
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$1.32B
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$73.7M
3
SLRN
ACELYRIN
SLRN
+$37.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.3M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$61.1M
2
ONC
BeOne Medicines Ltd
ONC
+$20.5M
3
FATE icon
Fate Therapeutics
FATE
+$14.8M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.3M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 54.66%
2 Consumer Discretionary 41.39%
3 Miscellaneous 3.23%
4 Technology 0.24%
5 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BZ icon
76
Kanzhun
BZ
$6.92B
$3.31M 0.1%
+220,000
New +$3.68M
TRML
77
DELISTED
Tourmaline Bio
TRML
$2.78M 0.09%
91,426
– –
CGEM icon
78
Cullinan Oncology
CGEM
$1.31B
$2.69M 0.08%
250,000
– –
STOK icon
79
Stoke Therapeutics
STOK
$1.87B
$2.66M 0.08%
250,000
– –
KRON
80
DELISTED
Kronos Bio
KRON
$2.65M 0.08%
1,542,954
– –
NBP
81
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$2.54M 0.08%
850,000
– –
SANA icon
82
Sana Biotechnology
SANA
$958M
$2.38M 0.07%
400,000
– –
ACHL
83
DELISTED
Achilles Therapeutics
ACHL
$2.13M 0.07%
2,255,375
– –
V icon
84
Visa
V
$701B
$1.78M 0.06%
+7,500
New +$1.72M
ADAG
85
Adagene
ADAG
$228M
$1.48M 0.05%
1,000,000
– –
AMZN icon
86
Amazon
AMZN
$2.73T
$1.3M 0.04%
+10,000
New +$1.14M
XLO icon
87
Xilio Therapeutics
XLO
$58.8M
$1.18M 0.04%
32,143
– –
IRWD icon
88
Ironwood Pharmaceuticals
IRWD
$689M
$1.18M 0.04%
110,532
– –
ME
89
DELISTED
23andMe Holding Co
ME
$1.16M 0.04%
33,050
– –
CRVS icon
90
Corvus Pharmaceuticals
CRVS
$1.1B
$1.15M 0.04%
500,000
– –
CRIS icon
91
Curis
CRIS
$2.72M
$1.08M 0.03%
3,250
– –
ADAP
92
DELISTED
Adaptimmune Therapeutics
ADAP
$1.05M 0.03%
+1,133,775
New +$1.35M
MSFT icon
93
Microsoft
MSFT
$3.75T
$1.02M 0.03%
+3,000
New +$940K
TSHA icon
94
Taysha Gene Therapies
TSHA
$1.64B
$952K 0.03%
1,440,882
– –
HARP
95
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$710K 0.02%
100,000
– –
AMD icon
96
Advanced Micro Devices
AMD
$805B
$683K 0.02%
+6,000
New +$624K
UTHR icon
97
United Therapeutics
UTHR
$21.3B
$656K 0.02%
2,971
-310
-9% -$68.7K
CYCN
98
DELISTED
Cyclerion Therapeutics
CYCN
$572K 0.02%
138,955
-1
-0% -$5
CRWD icon
99
CrowdStrike
CRWD
$241B
$514K 0.02%
+14,000
New +$488K
DDOG icon
100
Datadog
DDOG
$82.6B
$492K 0.02%
+5,000
New +$418K
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2023 Portfolio in Review

As of Q2 2023, Artal Group held 142 positions worth $3.23B, up 92% from $1.68B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group deployed $1.36B of net new capital in Q2 2023, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was CAVA Group: 32,007,990 shares worth $1.31B.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $20.5M trimmed.

  • Artal Group's largest Q2 2023 buy was CAVA Group: 32,007,990 shares worth $1.31B.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2023, an estimated $73.7M increase.
  • Artal Group's biggest Q2 2023 reduction was BeOne Medicines Ltd, cutting an estimated $20.5M.
  • Artal Group fully exited WW International in Q2 2023, selling an estimated $61.1M.
  • Artal Group's ten largest holdings make up 69% of its $3.23B portfolio in Q2 2023.
  • Artal Group opened 24 new positions and closed 25 in Q2 2023.
  • Artal Group's portfolio value rose 92% quarter-over-quarter to $3.23B.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.